Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy

Despite promising preclinical results, average response rates to anti-VEGF therapies, such as bevacizumab, are reduced for most cancers, while incurring in remarkable costs and side effects. Currently, there are no biomarkers available to select patients that can benefit from this therapy. Depending...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebelo de Almeida, Cátia, Mendes, Raquel Valente, Pezzarossa, Anna, Gago, Joaquim, Carvalho, Carlos, Alves, António, Nunes, Vitor, Brito, Maria José, Cardoso, Maria João, Ribeiro, Joana, Cardoso, Fátima, Ferreira, Miguel Godinho, Fior, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286887/
https://www.ncbi.nlm.nih.gov/pubmed/32523131
http://dx.doi.org/10.1038/s42003-020-1015-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286887/
https://www.ncbi.nlm.nih.gov/pubmed/32523131
http://dx.doi.org/10.1038/s42003-020-1015-0

Ejemplares similares